Ector et al. uncover circadian heterogeneity across neuroblastoma cell models and link rhythmic strength to drug sensitivity. Their findings suggest that circadian competence may influence treatment outcomes, pointing to chronotherapy as a potential avenue for improving pediatric cancer care.